Top Markets
#1 MowCat MowCat +48.88%
#2 Audiera Audiera +27.80%
#3 Bermuda Shorts Bermuda Shorts +24.76%
#4 Biconomy Biconomy +22.49%
#5 Velvet Velvet +22.49%
#6 aPriori aPriori +20.85%
#7 Derive Derive +19.60%
#8 Quack AI Quack AI +18.95%
#9 SkyAI SkyAI +14.21%
#10 Geodnet Geodnet +12.09%
Coin of the day
MowCat MowCat
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
IMV Inc. IMV Inc.

IMV Inc.

IMV
Rang in Aktien #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Aktienkurs
$0.82959892
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$4.16M
Veränderung (1 Tag)
-0.04%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel IMV Inc. (IMV)

Kategorie

Healthcare
P/B-Verhältnis für IMV Inc. (IMV)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von IMV Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für IMV Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE